SecBot SecBot

ELUT drug pipeline

ELUTIA INC. · 1 rated drug
$0.8230
+0.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/510(k) submission
Time to marketNXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.

NXT-41 Updated Nov 8

What to watch

Watch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.

Bull case
  • Massive unmet need: Infection rates in breast reconstruction are reported as high as 23%, and 86% of surgeons surveyed say current matrices increase infection risk, while 96% expressed interest in NXT-41x (per company Q2 2026 survey data).
  • Fully funded through launch: Elutia has secured ~$26M via a $15M Avenue Capital loan, $8M SimpliDerm sale, and $8M Boston Scientific escrow payment, with no equity dilution to shareholders. Company says it is funded into 2029.
  • Validated platform: Elutia's drug-eluting biomatrix technology was proven through its prior BioEnvelope/EluPro product for cardiac devices, which was sold to Boston Scientific for $88M.
Bear case
  • Binary regulatory risk: The NXT-41 clearance decision (Q4 2026) and NXT-41x clearance (Q2 2027) are binary events. A denial or delay would severely impact the stock given the company's single-product focus.
  • Micro-cap volatility: Stock trades around $0.84 with thin volume (~85K shares/day average). The company previously faced Nasdaq non-compliance when the stock fell below $1.00 in late 2025 (since resolved).
  • Competitive landscape: The biologic mesh/surgical matrix market includes established players (Allergan/AbbVie, Integra LifeSciences, MTF Biologics) with existing acellular dermal matrix products. NXT-41x's antibiotic-eluting differentiation is novel but unproven at commercial scale.